About Vaderis

Image Name

Vaderis is a biotechnology company focusing on treatment of rare and Orphan Diseases caused by Vascular Malformations.

Vaderis aims to be the first company in the world to develop a medicine for a rare Orphan disease called Hereditary Haemorrhagic Telangiectasia (HHT). The disease is sometimes known as Osler–Weber–Rendu disease.

Vaderis is developing an oral medicine which, if successful, will both treat the symptoms of HHT and will reduce the occurrence of new lesions, thereby modifying disease progression.

Medical Need

Image Name

There is a group of rare disorders caused by abnormal formation of blood vessels (“Vascular Malformations”) for which there are currently no available treatments. Afflicted patients usually have a genetic deficiency causing their condition. Patients develop over-growths of the vasculature causing lesions (known medically as telangiectasia or arteriovenous malformations).

These can occur either inside the body or onits surface (skin or mucosa). These lesions are delicate and subject to rupture causing unpredictable and uncontrolled bleeding leading to chronic conditions such as iron deficiency and often requiring blood transfusions. One of the most prominent of all diseases caused by Vascular Malformations is known as HHT, or Hereditary Haemorrhagic Telangiectasia.

More than half of HHT patients suffer from lesions in the lung, brain and/or liver, sometimes resulting in life-threatening events such as pulmonary haemorrhage, stroke or brain abscess. There are no treatments approved to address this disease and patients currently rely on interventions which, at best, only manage their symptoms.

Our Partners